Processa Pharmaceuticals Inc PCSA shares are trading higher by 36.9% to $0.28 during Friday’s session after the company announced plans to expand the development of Next Generation Capecitabine (“NGC-Cap”) into the treatment of advanced or metastatic breast cancer.
What Else?
Following discussions with the FDA, the company has decided to conduct a Phase 2 trial in breast cancer, supported by previously generated data from past studies. The company says this move is seen as a logical progression, considering the larger market for breast cancer compared to colorectal cancer.
The FDA and Processa believe that developing NGC-Cap for breast cancer will lead to a more efficient development program and increase the likelihood of FDA approval.
The Phase 2 trial aims to demonstrate the safety and efficacy of NGC-Cap over existing treatments, with plans to initiate the study in the third quarter of 2024.
See Also: Fed’s Goolsbee Expects Interest Rates To Fall With Inflation
According to data from Benzinga Pro, PCSA has a 52-week high of $1.27 and a 52-week low of $0.18.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
